상세 보기
Erratum to 'Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial' [Clin Mol Hepatol 2024;30:807-823]
- Yim, Sun Young;
- Lee, Sung Hwan;
- Baek, Seung-Woo;
- Sohn, Bohwa;
- Jeong, Yun Seong;
- ... Kang, Sang-Hee;
- ... Kim, Ji Hoon;
- 외 8명
Citations
WEB OF SCIENCE
0Citations
SCOPUS
1초록
In the original publication of this paper, the second graph in Figure 4B was erroneously identical with fourth graph in Figure 4B and correct version is provided below. We apologize for any inconvenience that may have been caused. The original article has been corrected as of 27th February 2025. © 2025 by Korean Association for the Study of the Liver.
- 제목
- Erratum to 'Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial' [Clin Mol Hepatol 2024;30:807-823]
- 저자
- Yim, Sun Young; Lee, Sung Hwan; Baek, Seung-Woo; Sohn, Bohwa; Jeong, Yun Seong; Kang, Sang-Hee; Park, Kena; Park, Hyewon; Lee, Sunyoung S; Kaseb, Ahmed O; Park, Young Nyun; Leem, Sun-Hee; Curran, Michael A; Kim, Ji Hoon; Lee, Ju-Seog
- 발행일
- 2025-04
- 유형
- Correction
- 권
- 31
- 호
- 2
- 페이지
- 669 ~ 670
- 언어
- ENG
- 출판사
- 대한간학회
- 발행국가
- 대한민국
- 분량
- 2 페이지
- ISSN
- E 2287-285X
P 2287-2728